Inovio Pharmaceuticals
35 hedge funds and large institutions have $15.7M invested in Inovio Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 11 increasing their positions, 3 reducing their positions, and 6 closing their positions.
318% more capital inflows, than outflows
Capital inflows: $3.04M | Capital outflows: $729K
267% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 3
167% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 6
40% more funds holding
Funds holding: 25 → 35 (+10)
0.26% more ownership
Funds ownership: 3.74% → 4% (+0.26%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$787K |
| 2 |
Bank of New York Mellon
New York
|
+$421K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$371K |
| 4 |
BlackRock Institutional Trust
San Francisco,
California
|
+$280K |
| 5 |
Moore Capital Management
New York
|
+$175K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWMDMG
Austin W. Marxe & David M. Greenhouse
New York
|
-$476K |
| 2 |
JP Morgan Chase
New York
|
-$121K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$57K |
| 4 |
Nomura Holdings
Tokyo,
Japan
|
-$46K |
| 5 |
United Asset Strategies
Garden City,
New York
|
-$10K |
INO Hedge Fund Activity: Q3 2013 in Review
35 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q3 2013, worth a combined $15.7M — up 193% from $5.36M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new INO positions and 6 closed out — a net gain of 10 holders — while 11 added to existing stakes and 3 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $787K. The largest seller was Austin W. Marxe & David M. Greenhouse, exiting entirely with an estimated $476K sold.
- 35 institutional investors held Inovio Pharmaceuticals (INO) as of Q3 2013, up from 25 in Q2 2013.
- Funds reported $15.7M of Inovio Pharmaceuticals stock for Q3 2013, up 193% quarter-over-quarter.
- 16 funds opened new Inovio Pharmaceuticals positions in Q3 2013 and 6 closed out, a net change of +10 holders.
- The largest Inovio Pharmaceuticals buyer in Q3 2013 was Morgan Stanley, an estimated $787K added.
- The largest Inovio Pharmaceuticals seller in Q3 2013 was Austin W. Marxe & David M. Greenhouse, an estimated $476K sold.
Based on aggregated 13F filings for Q3 2013.